China's pharmaceutical industry has experienced the low of 2006, adverse economic rebound in 2007 after starting in 2008, China's pharmaceutical industry has come dawn, 2008, China's pharmaceutical industry realized total output 758.3 billion yuan, up 23%; to achieve a total profit of 74.9 billion yuan, up 24%, developed rapidly.
Starting from 2009, in the new Medical reform Driven, China's pharmaceutical industry is to increase horsepower high-speed development, first half of 2009, the added value of China's medical line grew 14% in June up 13.9% 855 000 000 000 new medical reform the huge investment has brought about tremendous market demand, the demand has attracted the attention of multinational pharmaceutical group.
New medical reform can bring multinational pharmaceutical group What?
New medical reform plan to the pharmaceutical industry in China provides a large-scale expansion of opportunities, particularly for essential drugs system covering urban and rural residents in establishing a basic medical and health system, expanding the medical services market, especially in the rural market, which seems has been focused on high-end market, foreign multinational pharmaceutical companies have no effect, however, is not so.
Investment adviser in the pharmaceutical industry where researchers Guo Li said the new medical reform in practice is an opportunity to bring foreign multinational pharmaceutical companies, but also the opportunity for them, desired to put forward soon after the new medical reform, some multinational pharmaceutical groups have to fast on the pace of the market, have set up R & D centers in China and production base, to points a piece of the new health care reform, 850 billion market for multinational pharmaceutical companies put into making immediate access to the Chinese market.
Guo who he felt, even at this stage could undermine the interests of multinational pharmaceutical companies, they are still this way, because the long term, and now it's all worth it, they may give up to make high profits for their patent medicines and low keys for generics market profits, they may also expand their previous disdain for second-line, third tier cities and even rural markets, they now bow will allow the future to get more.
In fact, all fought in generics and expand the rural market into the Chinese market or to intensify the pace of R & D center and production base established multinational pharmaceutical companies are adjusting their policies to adapt to a manifestation of the new medical reform, which by adjusting those strategies, want price advantage to enter into a new medical reform in the past, in general, new medical reform will facilitate the continued expansion of the pharmaceutical market, will bring a lot of demand for foreign pharmaceutical companies.
However, the arrival of their domestic pharmaceutical enterprises will create some adverse effects, and now, in China Sell Pharmaceutical products, foreign and domestic companies the proportion is almost half and half, and now fought in foreign generic low profits and rural markets, to seize the resources and markets, reducing market share of Chinese pharmaceutical companies, which for my medicine pharmaceutical companies, especially small and medium enterprises is a major challenge, if the Chinese SMEs do not implement some mergers and acquisitions, then the system will be in the essential drugs and foreign multinational pharmaceutical companies of "pincer attack from both inside and outside" the brink of extinction at the edge of the next.
New medical reform will impact multinational pharmaceutical group?
1, new medical reform will lead to the production of transnational pharmaceutical companies and research centers to transfer to China
Since Lilly R & D headquarters in Shanghai, China, Europe's largest pharmaceutical group Sanofi - Aventis settled in Beijing on the world's fourth-largest R & D center, the business involved in drug development and clinical studies based on more than side, while Bayer in Beijing R & D centers worldwide, Roche started investing 400 million yuan in Shanghai Roche Pharmaceutical Plant Expansion Project in China set up Asia's drugs Cooperation Foreign Ministry have explained to adjust strategies to meet the arrival of a new medical reform.
Guo Fan Li pointed out that 850 billion a tremendous market demand to increase the pace of pharmaceutical companies to promote foreign investment into the Chinese market, while market access to China mainly on the establishment of R & D center and production base to achieve, these companies have in common is the cost savings significant to develop the domestic market in China, leading enterprises and local partnerships, and finally to gradually control the local distribution network, their every step towards a new medical reform is a huge market demand away. Guo Li-Wei
who believe that the ongoing medical reform in China on multinational pharmaceutical companies is a good opportunity, on the one hand, the Chinese Government to increase investment in the field of medicine, universal health services, will increase China's demand for pharmaceutical products; On the other hand, multinational pharmaceutical companies in disease prevention, vaccine development and production aspects of living in the world's leading level, new medical reform makes the conduct of multinational pharmaceutical groups can participate, on the multinational pharmaceutical group is also a good opportunity. I am an expert from grid-antenna.com, while we provides the quality product, such as Rfid Antenna Manufacturer , China Sector Antennas, Sector Antennas,and more.
Related Articles -
Rfid Antenna Manufacturer, China Sector Antennas,
|
